• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Safety Signal Evaluation of a Risk of Syncope and Dizziness Not Related to Bleeding or Stroke in Direct Oral Anticoagulant-Treated Patients
Clin Ther. 2023 Jan 16:S0149-2918(22)00416-7. doi: 10.1016/j.clinthera.2022.12.010. Online ahead of print.ABSTRACTPURPOSE: In clinical studies, rivaroxaban treatment has been associated with increased incidence of syncope not related to bleeding, anemia, or stroke. The study objective was to evaluate the occurrence of dizziness and/or syncope not related to bleeding, anemia, or stroke in patients treated with direct oral anticoagulants (DOACs).METHODS: A retrospective, observational, comparative study of adult patients diagnosed with atrial fibrillation and treated with DOACs was conducted using digital retrieval of medica...
Source: Clinical Therapeutics - January 18, 2023 Category: Drugs & Pharmacology Authors: Ophir Lavon Daisy Cohen Source Type: research

Management of Anticoagulation in Cancer Patients with Atrial Fibrillation
Isr Med Assoc J. 2022 Mar;24(3):183-185.ABSTRACTAtrial fibrillation is becoming an increasingly important problem in cardio-oncology. Specific risk factors for atrial fibrillation occurrence include type of cancer disease and anticancer drugs. Anticoagulation is often abandoned. The CHA2DS2-VASc and CHA2DS2 scores may be important not only in predicting stroke but also in mortality. The role of new direct oral anticoagulants is growing, but they need to be used in a personalized approach depending on the risk of unbeneficial interactions with cancer treatment and the risk of bleeding.PMID:35347933
Source: The Israel Medical Association Journal - March 29, 2022 Category: General Medicine Authors: Sebastian Szmit Jaros ław Kępski Michal Wilk Source Type: research

Pages: 1  2  3